US equities |
MU $877.55 ▲+2.46% NVDA $210.96 ▼-0.59% SPCX $147.49 ▲+1.89% AAPL $347.73 ▼-0.14% TSLA $372.22 ▼-0.63% SNDK $1,238.03 ▼-1.82% META $642.62 ▼-0.96% AMD $516.79 ▲+1.74%
FinancialContent

Axogen, Inc. - Common Stock (NQ:AXGN)

38.06 +1.38 (+3.76%)
Delayed Quote Updated: 4:00 PM EDT, Oct 23, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Axogen, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Axogen Announces New VP of Operations and Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
Craig Swandal, experienced medical device manufacturing executive, joins leadership team 
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Reports Preliminary Unaudited Revenue for Fourth Quarter and Full-Year 2024
From Axogen, Inc.
Via GlobeNewswire
News headline image
12 Health Care Stocks Moving In Thursday's Intraday Session ↗
 
Via Benzinga
News headline image
Axogen Earnings Preview ↗
 
Via Benzinga
News headline image
Axogen, Inc Reports Third Quarter 2024 Financial Results and Provides BLA Update
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to report third quarter 2024 financial results and host conference call on November 7, 2024
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Completes Submission of Biologics License Application to U.S. Food and Drug Administration for Avance Nerve Graft®
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Reports Inducement Grant to New Employee Under NASDAQ Listing Rule 5635(C)(4)
From Axogen, Inc.
Via GlobeNewswire
News headline image
CytoSorbents Appoints Peter J. Mariani Chief Financial Officer
CytoSorbents CFO Kathleen P. Bloch Retires 
From CytoSorbents
Via GlobeNewswire
News headline image
AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q2 2024 ↗
AXGN stock results show that Axogen beat analyst estimates for earnings per share and beat on revenue for the second quarter of 2024. 
Via InvestorPlace
News headline image
Parker-Hannifin Posts Upbeat Earnings, Joins Under Armour, Zillow Group, YETI Holdings, Eli Lilly And Other Big Stocks Moving Higher On Thursday ↗
 
Via Benzinga
News headline image
Axogen, Inc. Announces New Leadership Appointments
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. Reports Second Quarter 2024 Financial Results
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Report Second Quarter 2024 Financial Results and Host Conference Call on August 8, 2024
From Axogen, Inc.
Via GlobeNewswire
News headline image
Company Reports Inducement Grants to Non-Executive New Employee Under Nasdaq Listing Rule 5635(C)(4)
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc Announces Full Launch of Avive+ Soft Tissue Matrix™
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Processing Center (APC) Celebrates its Opening with Ohio Leaders in Vandalia
Showcasing Axogen’s Dedication to Fueling Ohio’s Biotechnology Sector Growth 
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc to Participate at Leerink Partners Healthcare Crossroads Conference
From Axogen, Inc.
Via GlobeNewswire
News headline image
AXGN Stock Earnings: Axogen Beats EPS, Misses Revenue for Q1 2024 ↗
AXGN stock results show that Axogen beat analyst estimates for earnings per share but missed on revenue for the first quarter of 2024. 
Via InvestorPlace
News headline image
Axogen, Inc Reports First Quarter 2024 Financial Results
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen Announces First Surgical Implants of Avive+ Soft Tissue Matrix™
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. to Report First Quarter 2024 Financial Results and Host Conference Call on May 2, 2024
From Axogen, Inc.
Via GlobeNewswire
News headline image
Why SOPHiA GENETICS Shares Are Trading Lower By 19%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session ↗
Shares of SOPHiA GENETICS SA (NASDAQ: SOPH) fell sharply during Tuesday’s session after the company reported worse than expected fourth-quarter earnings and issued 2024 guidance. 
Via Benzinga
News headline image
AXGN Stock Earnings: Axogen Beats EPS, Beats Revenue for Q4 2023 ↗
AXGN stock results show that Axogen beat analyst estimates for earnings per share and beat on revenue for the fourth quarter of 2023. 
Via InvestorPlace
News headline image
Axogen, Inc Reports 2023 Fourth Quarter and Full-Year Financial Results
From Axogen, Inc.
Via GlobeNewswire
News headline image
Earnings Scheduled For March 5, 2024 ↗
Companies Reporting Before The Bell • NIO (NYSE:NIO) is estimated to report quarterly loss at $0.51 per share on revenue of $2.29 billion. 
Via Benzinga
News headline image
Axogen, Inc. to Report 2023 Fourth Quarter and Full-Year Financial Results on March 5, 2024
From Axogen, Inc.
Via GlobeNewswire
News headline image
Company Reports Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)
From Axogen, Inc.
Via GlobeNewswire
News headline image
Axogen, Inc. Announces Positive Topline Results from REPOSE, a Prospective, Randomized Clinical Trial of Axoguard Nerve Cap
From Axogen, Inc.
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 Next >